Acumen Pharmaceuticals
ABOS
61 hedge funds and large institutions have $113M invested in Acumen Pharmaceuticals in 2023 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 17 increasing their positions, 22 reducing their positions, and 9 closing their positions.
11% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 9
2% more funds holding
Funds holding: 60 → 61 (+1)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
3.84% less ownership
Funds ownership: 71.48% → 67.65% (-3.8%)
23% less repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 22
27% less call options, than puts
Call options by funds: $206K | Put options by funds: $284K
29% less capital invested
Capital invested by funds: $158M → $113M (-$45.2M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Walleye Capital
New York
|
+$954K |
| 2 |
JGC
J. Goldman & Co
New York
|
+$705K |
| 3 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
+$611K |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
+$349K |
| 5 |
Jane Street
New York
|
+$336K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PFO
Pathstone Family Office
Englewood,
New Jersey
|
-$3.49M |
| 2 |
BlackRock
New York
|
-$2.47M |
| 3 |
PA
Perceptive Advisors
New York
|
-$1.88M |
| 4 |
GPC
Guardian Point Capital
Charlottesville,
Virginia
|
-$888K |
| 5 |
SCM
Silverarc Capital Management
Boston,
Massachusetts
|
-$774K |
ABOS Hedge Fund Activity: Q1 2023 in Review
61 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Acumen Pharmaceuticals (ABOS) for Q1 2023, worth a combined $113M — down 29% from $158M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new ABOS positions and 9 closed out — a net gain of 1 holder — while 17 added to existing stakes and 22 trimmed.
The largest buyer was Walleye Capital, adding an estimated $954K. The largest seller was Pathstone Family Office, cutting an estimated $3.49M.
- 61 institutional investors held Acumen Pharmaceuticals (ABOS) as of Q1 2023, up from 60 in Q4 2022.
- Funds reported $113M of Acumen Pharmaceuticals stock for Q1 2023, down 29% quarter-over-quarter.
- 10 funds opened new Acumen Pharmaceuticals positions in Q1 2023 and 9 closed out, a net change of +1 holder.
- The largest Acumen Pharmaceuticals buyer in Q1 2023 was Walleye Capital, an estimated $954K added.
- The largest Acumen Pharmaceuticals seller in Q1 2023 was Pathstone Family Office, an estimated $3.49M sold.
Based on aggregated 13F filings for Q1 2023.